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Research Intracerebroventricular injection of leukotriene B4 
attenuates antigen-induced asthmatic response 
via BLT1 receptor stimulating HPA-axis in sensitized 
rats
Shui-Juan Zhang†1,2, Yang-Mei Deng†1, Yi-Liang Zhu1, Xin-Wei Dong1, Jun-Xia Jiang1 and Qiang-Min Xie*1
Abstract
Background: Basic and clinical studies suggest that hypothalamic-pituitary-adrenal (HPA) axis is the neuroendocrine-
immnue pathway that functionally regulates the chronic inflammatory disease including asthma. Our previous studies 
showed corresponding changes of cytokines and leukotriene B4 (LTB4) between brain and lung tissues in antigen-
challenged asthmatic rats. Here, we investigated how the increased LTB4 level in brain interacts with HPA axis in 
regulating antigen-induced asthmatic response in sensitized rats.
Methods: Ovalbumin-sensitized rats were challenged by inhalation of antigen. Rats received vehicle, LTB4 or U75302 (a 
selective LTB4 BLT1 receptor inhibitor) was given via intracerebroventricular injection (i.c.v) 30 min before challenge. 
Lung resistance (RL) and dynamic lung compliance (Cdyn) were measured before and after antigen challenge. 
Inflammatory response in lung tissue was assessed 24 h after challenge. Expression of CRH mRNA and protein in 
hypothalamus were evaluated by RT-PCR and Western Blot, and plasma levels of adrenocorticotropic hormone (ACTH) 
and corticosterone (CORT) were measured using the ELISA kits.
Results: Antigen challenge decreased pulmonary function and induced airway inflammation, evoked HPA axis 
response in sensitized rats. Administration of LTB4 via i.c.v markedly attenuated airway contraction and inflammation. 
Meanwhile, LTB4 via i.c.v markedly increased CORT and ACTH level in plasma before antigen challenge, and followed by 
further increases in CORT and ACTH levels in plasma after antigen challenge in sensitized rats. Expression of CRH mRNA 
and protein in hypothalamus were also significantly increased by LTB4 via i.c.v in sensitized rats after antigen challenge. 
These effect were completely blocked by pre-treatment with BLT1 receptor antagonist U75302 (10 ng), but not by BLT2 
antagonist LY255283.
Conclusions: LTB4 administered via i.c.v down-regulates the airway contraction response and inflammation through 
activation of the HPA axis via its BLT1 receptor. This study expands our concept of the regulatory role of intracranial 
inflammatory mediators in inflammatory diseases including asthma. The favourable effects of LTB4 on the HPA axis may 
help to explain the phenomenon of self-relief after an asthmatic attack.
Background
Central nervous system (CNS) and neuroendocrine-
immune systems (NEI) are the two major systems which
respond adaptively to the numerous challenges to main-
tain the physiological homeostasis. The adaptive
responses could be impaired by some physical and psy-
chological stressors in neuroendocrine-immune feedback
system. Such dysfunction could also contribute to the
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pathogenesis of allergic or autoimmune diseases [1]. The
studies on the cross-talk between neuroendocrine and
immune systems added further evidences that interac-
tions among the neural, neuroendocrine and immune
systems are bidirectional [1-3]. Recent studies have
shown that this bidirectional cross-talk is based on the
secretion of pro-inflammatory factors including media-
tors and cytokines, hormones, neurotransmitters and
neuropeptides [4-6]. The hypothalamic-pituitary-adre-
nal (HPA) axis is the major pathway in NEI, hypothala-
mus secretes corticotropin releasing hormone (CRH)
when the HPA axis is activated. This molecule travels to
the anterior pituitary gland, which responds to its pres-
ence by secreting a pulse of adrenocorticotropin hor-
mone (ACTH). The ACTH signal is carried through the
peripheral circulation to the adrenal glands, which syn-
thesize and release cortisol and lead to reduction of
inflammation.
Leukotriene (LT) B4 is a product of the action of LTA4
hydrolase (LTA4-H) on LTA4 in 5-lipoxygenase (5-LO)
pathway. It is a potent leukocyte chemoattractant and
activator, which plays an important role in modulating
immune and inflammatory responses [7]. An early study
showed that LTB4 increases CRH secretion in explanted
and cultured hypothalamus via autocrine/paracrine or as
endocrine factor [8]. Further studies found that inflam-
matory mediator such as IL-1, IL-6 can activate the HPA
axis and regulate the inflammatory response in periphery
[9]. From previous work, we found that the changes of
Th1/Th2 paradigm (ratio of interferon [IFN]-gamma/
interleukin [IL]-4 decreased) [10], and the content of
LTB4 in the cerebral cortex increases corresponding to
their changes in bronchoalveolar lavage fluid (BALF) or
lung tissue in inflammatory status of asthmatic rats [11].
Also, the expression of 5-LO and LTA4-H mRNA in cere-
bral cortex of asthmatic rats are significantly higher than
those of control rats [12]. All these findings indicate that
the changes of these proinflammatory mediators in the
CNS may have pathophysiologic effects in asthmatic rats.
So far, it is unclear how LTB4 in the CNS regulates
inflammation in lung tissue of asthma. Based on these
studies, we postulate that the increase of LTB4 in brain
activates NEI, which may regulate asthmatic response in
rats. To explore this hypothesis, rats were actively sensi-
tized with ovalbumin (OVA), and LTB4 was administered
via intracerebroventricular injection (i.c.v). The pulmo-
nary function and inflammatory cell infiltration in lung
were evaluated. Meanwhile, the HPA axis activity was
also explored by measuring CRH mRNA and protein
expression in hypothalamus, corticosterone (CORT) and
ACTH level in plasma during antigen challenge in sensi-
tized rats.
Methods
Animal and study design
Sprague-Dawley (SD) rats of either sex weighing 180~200
g were purchased from Laboratory Animal Center in
Medical Science College of Zhejiang University (Grade II,
Certificate No. 220010014). All animals were housed in
Plexiglas cages and kept on a 12/12 h light-dark cycle in
temperature and humidity controlled rooms, standard
l a b o r a t o r y  f o o d  a n d  w a t e r  w e r e  p r o v i d e d  a d  l i b i t u m .
Food was withheld 8 hours before the experiments, with
free access to water. Unless otherwise indicated, Animal
treatments were strictly in accordance with the China
Community Guidelines for the Use of Experimental Ani-
mals and the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. Rats were assigned
to different treatments, Vehicle-sham group was as nor-
mal control, ovalbumin (OVA) sensitized and challenged
rats were treated as asthmatic model (Vehicle-OVA), the
effects of LTB4 (LTB4-OVA) via i.c.v on asthmatic rats
were evaluated. And U75302, the selective BLT1 receptor
antagonist, was administered via i.c.v alone (U75302-
OVA) or 5 min before LTB4 dosing (U75302-LTB4-OVA).
Sensitizing procedures
To sensitize the rats, 1 mg OVA (Grade V, Sigma Chemi-
cal Co., St. Louis, MO) absorbed in 100 mg aluminium
hydroxide adjuvant in 1.0 ml saline. Each rat was intrap-
eritonealy injected (i.p) with 0.5 ml, and subcutaneously
injected (s.c) with 0.05 ml/site at four footpads (4 sites),
neck (one site), back (3 sites), and two groins (2 sites),
respectively. Then, every rat was injected (i.p) with 1 ×
1010 bordetella pertussis adjuvant (Shanghai Institute of
Biological Products, China) on experiment day 0. Normal
control (vehicle-sham) rats were injected with only alu-
minium hydroxide adjuvant in saline following the same
protocol. At day 14 after sensitization, the rats were
placed in a 45 cm × 45 cm × 15 cm plastic box and chal-
lenged by exposure to an aerosol of OV A (20 mg/ml in
saline), which was generated in a jet nebulizer (particle
size 1-5 μm; BARI, MASTER, Germany) for 20 min, and
repeated daily to day 21 after sensitization. Vehicle-sham
rats were similarly exposed to an aerosol of saline.
Intracerebroventricular injection
After 10% chloral hydrate (3 ml/kg i.p) anaesthesia, the
animal's head was fixed in a stereotaxic apparatus (SR-
6N, Narishige, Japan). The procedure of i.c.v. injection
was in accordance with rat brain graph described by
George Paxious and Charles Watson, and with minor
improvement as described by Mauser et al [13]. In brief, a
midline incision was made from a point just posterior to
the eyes to about 3 cm caudal, and the overlying connec-
tive tissue was removed to expose the skull. A small holeZhang et al. Respiratory Research 2010, 11:39
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(about 2 mm in diameter) was opened perpendicularly to
the skull, -1.0 or -1.5 mm anterior and 1.5 mm lateral to
the bregma by using a dental drill (Minimo, Japan). A
stainless steel guide cannula (internal diameter, 0.5 mm;
length, 1.5 cm) was then slowly and vertically lowered to
a depth of 3.8 mm from the dura into lateral ventricles.
The guide cannula was then held in place by dental
cement (oral cavity drugs and materials of Wuhan Uni-
versity, China) with a small anchor screw. The scalp was
sutured and the animals were left to recover for 1 week
before the first antigen challenge. All injections through
the i.c.v. were made with a Hamilton syringe (Reno, NV,
U.S.A.) and in a 10 μl volume of artificial CSF. In vehicle-
sham or LTB4-OVA group, vehicle 10 μl or LTB4 10 ng
(Sigma Chemical Co., St. Louis, MO) (Cayman Chemical)
was administered via i.c.v 30 min before the antigen chal-
lenge from day 14 to day 21. In the U75302-LTB4-OVA
group, an extra dose of U75302 10 ng was administered
via i.c.v 5 min before LTB4 dosing.
Measurement of pulmonary function
The lung function was assessed 30 min before and after
LTB4 i.c.v on day 21 after sensitization as described previ-
ously [14]. Briefly, each anaesthetized rat was placed
supine inside a Plexiglas whole-body plethysmograph.
The flow rate was monitored with a Fleisch tube con-
nected to the airway in a pressure transducer. Changes in
lung volume were measured by detecting pressure
changes in the plethysmographic chamber through a port
in the connecting tube with a pressure transducer. To
measure pleural pressure, a needle (No. 16) with a multi-
holed tip was directly inserted into the pleural cavity
(between fourth and fifthly rib at left thorax) through a
port in the connecting tube with a differential pressure
transducer. Transpulmonary pressure was calculated as
the difference between mouth and pleural pressure. All
signals of pressure transducers were continuously com-
puted (MedLab, Nanjing Biotech Instruments, China) by
fitting flow, volume, and pressure to an equation of
motion. For antigen challenge, OVA 20 mg/ml dissolved
in saline aerosolized by a jet nebulizer (BARI Co. Ltd,
Germany) for 5 min. The respiratory waveform was mon-
itored for 15 min and maximal changes from baseline for
each parameter were recorded by the MedLab. The
results were shown as airway resistance (RL) and dynamic
lung compliance (Cdyn) value before and after antigen
challenge.
Preparation of bronchoalveolar lavage fluids
Twenty-four hours after the final OVA challenge, rats
were anesthetized with urethane (2 g/kg, i.p.). Bronchoal-
veolar lavage fluids (BALF) were obtained via tracheal
tube by washing of the right lung with 1 ml of sterilized
saline containing 1% bovine serum albumin (BSA) and 5
IU/ml heparin for three times. The total number of cells
in the BALF was counted. The BALF was centrifuged for
10 min at 400 × g at 4°C. Two hundred cells from the cell
suspension were stained by Wright-Giemsa and classified
using a light microscope. The results were expressed as
the numbers of each type of cell population in 1 ml of
BALF.
Lung histopathology
The left lung was fixed in 10% neutral formalin for 7 days.
Sections of 5 μm thickness were prepared and stained
with hematoxylin-eosin (H&E). To determine the severity
of inflammatory cell infiltration, peribronchial eosinophil
cell number was blindly counted and the severity was
evaluated by a 5 point scoring system described previ-
ously [15]. Briefly, the scoring system was 5-marked, 4-
moderate, 3-medium, 2-mild, 1-minimal and 0-no
eosinophil cells.
ACTH and CORT assay
Blood samples were collected in heparin-coated tubes via
the tail vein 30 min before, 30 min after LTB4 i.c.v, and 30
min after final antigen challenge. Blood samples were
centrifuged at 2000 × g to separate plasma at 4°C for 15
min. All samples were stored at -80°C until analysis. The
l e v e l s  o f  A C T H  a n d  C O R T  i n  p l a s m a  w e r e  m e a s u r e d
using a commercial ELISA kit (USCN-LIFE™, China) by
following the manufacturer's instructions.
Isolation of hypothalamus
Rats were euthanized and then decapitated 24 h after the
final antigen challenge. Hypothalamus was dissected with
the following limits: anterior border of the optic chiasm,
anterior border of the mamillary bodies, and lateral hypo-
thalamic sulci. The depth of dissection was approximately
3 mm. The hypothalamus was then quickly frozen in liq-
uid nitrogen and preserved at -80°C for extraction of
RNA or protein.
Reverse transcription and polymerase chain reaction
Total RNA was isolated with TRIzol Reagent (Invitrogen,
USA). First-strand cDNA was generated from 4 μg of
total RNA using oligo-dT to prime the reverse transcrip-
tion according to the supplied protocol (Invitrogen). PCR
were performed using commercial PCR reagents Kit
(TaKaRa) in a gradient thermal cycler PCR machine
(Eppendorf, Germany). Rat CRH was amplified using
primers 5'-TCACCTTCCACCTTCTGAGG-3' and 5'-
GGAAATGAAATGTTGCGCTT-3' (317 bp, intron
spanned) for 35 cycles (94°C 30 s, 58°C 45 s, 72°C 45 s).
Primers for rat GAPDH were 5'-ACCACCATGGA-
GAAGGCTGG-3' and 5'-CACAGTGTAGCCCAG-
GATGC-3' (528 bp, intron spanned) for 28 cycles (94°C
30 s, 58°C 30 s, 72°C 60 s). Aliquots of polymerase chain
reaction products were separated by electrophoresis onZhang et al. Respiratory Research 2010, 11:39
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1.5% agarose gels and visualized with ethidium bromide,
and the PCR product bands were quantified by using
UVP Gel Documentation system (UVP, Upland, CA).
Results were expressed as a ratio of densitometry value of
CRH to that of GAPDH.
Western Blot
CRH protein expression in hypothalamus was assessed as
described by Meloni EG et al [16]. 20 μg protein/lane
(determined by protein assay; Eppendorf Biophotometer,
Germany) was loaded onto a 6-well, 12% Bis-Tris gel
(Invitrogen) and electrophoresed in 1 × 2-N-morpholino-
ethane sulfonic acid (MES)-SDS running buffer (Invitro-
gen). After electrophoretic transfer, the polyvinylidene
fluoride (PVDF) membranes were cut to isolate the beta-
actin band as well as the lower molecular weight CRH
band. Membranes were incubated in blocking buffer (5%
non-fat dry milk in PBS and 0.1% Tween 20; PBS-T) over-
night at 4°C and then incubated with either polyclonal
rabbit anti-CRH (1:200; Santa Cruz Biotechnology) or
rabbit anti-beta-actin (1:1,000; Cell Signaling Technol-
ogy) antibody diluted in PBS-T for 2 h at room tempera-
ture. After incubation in secondary antibody (HRP-
conjugated goat anti-rabbit IgG, 1:5000; Li-cor Biosci-
ences) diluted in blocking buffer for 2 h, immunoreactiv-
ity was visualized with chemiluminescence using an
Image Station (Odyssey, American Gene Co.). Specific
CRH band was determined by the synthetic rat CRH
(rCRH, American peptide Company). Immunoblots were
quantified by image analysis (UVP, Upland, CA) and data
were expressed as a ratio of densitometry value of CRH to
that of beta-actin.
Statistical analysis
Numerical data were presented as means ± S.D. Statisti-
cal calculations were performed using SigmaStat software
(SigmaStat 2.0, SPSS Inc., Chicago, IL, USA), ANOVA
and Student-Newman-Keuls multiple comparisons test
were used to calculate the significance of differences of
respiratory function, inflammatory cells in BALF, levels
of CORT and ACTH in plasma, and expression of CRH in
hypothalamus. A non-parametric test, the Mann-Whit-
ney U-test, was used to compare differences in eosinophil
infiltration in airway. Significance was assessed at the P <
0.05 level.
Results
The changes of airway resistance and dynamic lung 
compliance
Compared with the baseline values, saline inhalation did
not show effects on the airway resistance (RL) and
dynamic lung compliance (Cdyn) in both vehicle-sham
rats and OVA-sensitized rats (data not shown). Bronchial
challenge of OVA induced significant increase of RL and
decrease of Cdyn with maximal response at 4~5 min in the
vehicle-OVA group. These responses were suppressed by
treatment of LTB4 via i.c.v as shown in the LTB4-OVA
group (P < 0.01), but not by U75302. However, U75302 at
10 ng via i.c.v. completely blocked the inhibitory effects of
LTB4 on antigen-induced increase of RL and decrease of
Cdyn in LTB4-U75302-OVA group (Fig. 1).
Airway inflammation
To further study the effect of LTB4  i.c.v on antigen-
induced airway inflammation, we evaluated the inflam-
matory cell infiltration in OVA sensitized rats. 24 h after
the final OVA challenge, inflammatory cells including
polymorphonuclear (PMN) cells (eosinophils and neutro-
phils) and monocytes (lymphocytes and macrophages) in
BALF were counted. The total inflammatory cells in
BALF of vehicle-OVA rats was 6-fold greater than that in
vehicle-sham rats. LTB4 10 ng (i.c.v) significantly
decreased the total inflammatory cells in BALF. Classifi-
cation of these inflammatory cells showed that in vehicle-
OVA rats, numbers of PMN and monocytes in the BALF
increased 11.6 and 4.2 fold, respectively, as compared
with those observed in vehicle-sham rats (Fig. 2). LTB4 10
ng (i.c.v) significantly decreased PMN in BALF. U75302
10 ng itself (i.c.v) did not alter the infiltration of inflam-
matory cells in airways, but almost fully blocked inhibi-
tory effects of LTB4 on the inflammatory cell numbers in
BALF (P < 0.01).
Eosinophil infiltration in lung tissues
Effect of LTB4 via i.c.v on antigen-induced inflammatory
response was also evaluated by lung histopathology. Lung
tissues were harvested 24 h after the final OVA challenge.
The vehicle-OVA rats exhibited an obvious eosinophil
cell infiltration into the peribronchiolar and perivascular
connective tissues as compared with vehicle-sham rats.
LTB4 10 ng (i.c.v) markedly inhibited the OVA-induced
eosinophil infiltration as compared with vehicle-OVA
rats (P  < 0.01), and the inhibitory effect of LTB4 was
blocked by U75302 (Fig. 3).
Plasma CORT and ACTH concentrations
To further test the hypothesis that LTB4 exert its inhibi-
tory effect via activation of HPA axis, we measured the
level of CORT and ACTH in plasma 30 min before and
after LTB4 administration, and 30 min after antigen chal-
lenge. Plasma CORT and ACTH concentrations did not
differ significantly before LTB4  i.c.v treatment in all
groups (Fig. 4). LTB4 via the i.c.v markedly increased
plasma CORT and ACTH secretion rate in the LTB4-
OVA group to 2.4 and 3.2 folds of the basal rate, respec-
tively. However, U75302, at the dose of 10 ng (i.c.v),
markedly blocked LTB4 induced increase of secretion ofZhang et al. Respiratory Research 2010, 11:39
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CORT and ACTH in plasma (P  < 0.01). Interestingly,
plasma CORT and ACTH concentrations in all treatment
groups increased significantly 30 min after antigen chal-
lenge, and LTB4 at 10 ng (i.c.v) additionally increased the
concentration of plasma CORT by 92.6%(P < 0.01) and
ACTH by 71.5% (P < 0.01) after antigen challenge as com-
pared with that after LTB4 i.c.v treatment. Furthermore,
compared with LTB4-OVA group, pretreatment with
U75302 at 10 ng also suppressed LTB4  i.c.v induced
increase of CORT and ACTH after antigen challenge. On
contrast, LY255283, a BLT2 antagonist (Cayman Chemi-
cal), did not significantly block LTB4 effects even at a
large dose (50 ng/kg, i.c.v) (data not shown). Compared
with the vehicle-OVA group, U75302 alone at 10 ng (i.c.v)
only decreased CORT (P > 0.05) and ACTH(P > 0.05)
level for around 15% to 20% in plasma after antigen chal-
lenge in U75302-OVA group when comparing with vehi-
cle-OVA group.
Expression of CRH mRNA and protein in hypothalamus
Expression of CRH mRNA and protein in hypothalamus
were evaluated in this study. We found that LTB4 alone
via the i.c.v or OVA challenge alone markedly increased
CRH mRNA and protein expression in sensitized rats.
Additionally, LTB4 via the i.c.v further increased OVA
challenge-induced CRH mRNA and protein expression in
hypothalamus in sensitized rats (Fig. 5A and 5B). Fur-
thermore, compared with LTB4-OVA group, U75302
alone decrease around 15% or 30% of CRH mRNA and
Figure 1 LTB4 via i.c.v attenuates the antigen-induced changes of 
pulmonary function in rats, and U75302 blocks the inhibitory ef-
fect of LTB4. On day 21 after ovalbumin sensitization, rats were chal-
lenged for 5 min with aerosolized 2% ovalbumin and the airway 
resistance (RL) (A) and dynamic lung compliance (Cdyn) (B) were mea-
sured before and 5 min after the antigen challenge. Data are expressed 
as the mean ± S.D of vehicle-sham (n = 8), vehicle-OVA (n = 10), LTB4-
OVA (n = 9), U75302-OVA (n = 9) and U75302-LTB4-OVA (n = 10). ##P < 
0.01 vs the vehicle-sham group; **P < 0.01 vs the vehicle-OVA group; 
††P < 0.01 vs the LTB4-OVA group.
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protein expression but was not statistically significant.
Pretreatment with U75302 at 10 ng via i.c.v suppressed
LTB4- i n d u c e d  i n c r e a s e  o f  C R H  m R N A  a n d  p r o t e i n
expression in antigen challenged sensitized rats. On con-
trast, LY255283 did not significantly block the effects of
LTB4 even at a large dose (50 ng/kg, i.c.v).
Discussion
R e c e n t  s t u d i e s  h a v e  e m p h a s i z e d  a n  i m p o r t a n t  r o l e  o f
inflammatory mediators in the regulation of neuroendo-
crine pathways during immune challenge and in pituitary
hormone secretion [17]. Particular emphasis is placed on
the cross-talk between inflammation and the HPA axis.
Studies have shown that inflammatory cytokines (IL-1,
IL-6 etc) activate the HPA axis with the increase of secre-
tion of cortisol, which in turn suppresses the inflamma-
tory and immune reaction [9]. During antigen-mediated
activation, CD4+ and CD8+ lymphocytes are able to pro-
duce hormones like ACTH, growth hormone (GH), thy-
roid stimulating hormone (TSH) and gonadotropins [18].
More directly, an antigenic challenge delivered either via
the i.c.v or i.v routes evokes an increased HPA axis
response in dogs that sensitized with IgE via the i.c.v
Figure 3 Lung histopathology. Haematoxalin and eosin-stained 
lung tissues were evaluated and scored for eosinophil cell infiltration. 
Compared with vehicle-sham group (A), marked infiltration of eosino-
phil cells in peribronchiolar space and perivascular space were ob-
served in the vehicle-OVA (B), there were no significant eosinophil cell 
infiltration presented in the group of LTB4-OVA (C). U75302-OVA (D) 
and U75302-LTB4-OVA (E) did not show any attenuation of eosinophil 
infiltration. Scores of eosinophil cell infiltration were graded on the ba-
sis of severity of inflammation (F). ##P < 0.01 vs the vehicle-sham 
group;**P < 0.01 vs the vehicle-OVA group;††P < 0.01 vs the LTB4-OVA 
group.
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route [19]. The activation of the HPA axis is also observed
in allergic rhinitis during nasal provocationand and in
cutaneous inflammatory disease [20,21]. Thus, the acti-
vated HPA axis inhibits the inflammation via increased
cortisol. Conversely, the deregulation of the HPA axis and
inability to increase glucocorticoid production in
response to stress is associated with increased airway
inflammation with mechanical dysfunction of the lungs
in asthma. For example, in CRH-knockout mice, the air-
way inflammation increased and lung mechanical func-
tion decreased with the increased IL-4 and IL-13 levels,
and impaired adrenal responses to stress in asthmatic
mice [22]. This is also in agreement with the clinical
observation that stressful life events increase the risk of a
new asthma attack [23]. All these studies indicate that the
crosstalk between inflammatory mediator and HPA axis
regulate asthma.
Evolving evidence indicates that LTB4 has an important
role in the development of asthma [24], and LTB4 medi-
ated effects are thought through two G-protein coupled
receptors (GPCRs), BLT1 (high affinity) and BLT2 (low
affinity) [25,26].
Interestingly, particularly high levels of neuronal 5-LO
expression and LTB4 content have been identified in CNS
upon challenge with a variety of stimuli [27,28]. Our pre-
vious study found that antigen challenge induces the
expression of 5-LO and LTA4H mRNA and LTB4 levels in
brain after antigen challenge in sensitized rats. And the
glucocorticoid examethasone inhibited the 5-LO and
LTA4-H mRNA expression in cerebral cortex in the asth-
matic rats [12]. In this study, we further evaluated the
functional effect of LTB4 in brain through exogenously
injection of LTB4 via i.c.v. We observed that antigen chal-
lenge or LTB4 injection via i.c.v alone activates the HPA
axis, while combination of both further increases the
HPA axis activation, which is manifested by the increased
CRH mRNA and protein expression in hypothalamus,
and increased ACTH and CORT level in plasma of sensi-
tized rats. The increased HPA activation was accompa-
nied by the alleviation of airway inflammation and
improvement of lung mechanical function in sensitized
rats. Using the selective receptor antagonist, we found
that pretreatment of BLT1 receptor antagonist U75302
via i.c.v, but not BLT2 antagonist, completely suppressed
LTB4 induced effects. In fact, the functional effect of LTB4
via i.c.v on HPA axis and peripheral asthmatic symptom
in this study was supported by other studies. For example,
it was found eicosaniods including LTB4 induces CRH
secretion in explanted and cultured hypothalamus from
rat [8]. And the deficiency of CRH worsen the airway
inflammation and lung mechanical disfunction in sensi-
tized mouse [22]. Base on these and aforementioned
observations, we postulate that the increase of LTB4 level
in brain induced by antigen challenge may acts as an
immunomodulator, stimulates HPA axis activity via its
selective BLT1 receptor, and the final increased cortisol
level attenuates antigen-induced airway contraction and
inflammation in the asthmatic model of rats.
Figure 5 LTB4 via i.c.v injection increases expression of CRH in the 
hypothalamus in sensitized rats. Representative blots and densi-
tometry analysis for expression of CRH mRNA by RT-PCR (A) and pro-
tein by Western blot (B). The blots are representative of three similar 
experiments, each run with independent samples. Data are expressed 
as the mean ± S.D. of each group (n = 3). #P < 0.05 vs the vehicle-sham 
group;†P < 0.05 vs the LTB4-OVA or LY255283-LTB4-OVA group
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It appears that different mechanisms in acute vs
chronic stress as the stimulator to the HPA axis influence
the inflammatory responses of the airway in asthma. It
supposed that acute stress cause the activation of HPA
axis and consequent cortisol release, lead to reduction of
airway inflammation. However, in chronic stress condi-
tion, after continuous prolonged or intermittent stimula-
tion, HPA axis activity is suppressed and its anti-
inflammatory effect is reduced [23]. For example, studies
found that acute stress or stress induced TNF-alpha or P
substance production enhances airway reactivity or
inflammation in OVA sensitized mice [29,30]. In adult
mice, exposure to short term stress (3 days) decrease the
inflammatory cell number in BALF, while the inflamma-
tory cytokines level increased after a long-term exposure
(7 days) [31]. In our study, continuous antigen attack (7
d a y s )  t o  s e n s i t i z e d  r a t s  i s  s u p p o s e d  t o  b e  t h e  c h r o n i c
stressor, but we observed the increase of CRH expression
in hypothalamus, ACTH and CORT level in plasma after
antigen challenge, which is contradictory to the opinion
of chronic stress inhibit of HPA axis. Our postulation is
that the antigen attack still provokes the acute airway
response in established disease state, which may acts as
acute stressor activate the NEI system and regulate the
HPA axis response.
We did not find significantly differences on airway
inflammation and lung mechanical function in sensitized
rats treated with U75302 alone via i.c.v, which may sug-
gest that the endogenous intracerebral LTB4 activity does
not normally play a large role in modulating airway
inflammation in this model. Notably, we observed a mild
decrease (around 15%-30%) in CRH expression in hypo-
thalamus or ACTH and CORT level in plasma after BLT1
was blocked by U75302 after antigen challenge. We pos-
tulate that the increased endogenous LTB4 induced by
antigen challenge may mildly activate the HPA axis, but
this activation of the HPA axis may be not enough to
antagonize peripheral inflammation in this asthmatic
model. Another possible explanation is that the func-
tional effect of increased endogenous LTB4 induced by
antigen challenge may be balanced by other mediators or
cytokines in brain. For example, the levels of Th2- (e.g IL-
4, IL-13) and Th1- cytokines (e.g INF-gamma) during
asthmatic attack in brain are also changed after antigen
challenge. Further studies are needed to clarify how the
HPA axis response to the change of asthma-related
cytokines and other inflammatory mediators, and how
the HPA axis communicates with neural and endocrine
networks as well as their signal pathways in regulating
peripheral allergic response.
Conclusions
This study finds that adminstration of LTB4 via i.c.v acti-
vates HPA axis via the BLT1 receptor, which may contrib-
ute to the attenuation of the airway inflammation and
decreased lung function in asthmatic status. This study
expands our concept of the regulatory role of intracranial
inflammatory mediators in inflammatory diseases
including asthma, and suggests a link between intracra-
nial LTB4 and neuroendocrine networks. In line with this
concept, these inflammatory factors probably have some
favourable effects on the HPA axis of asthmatics, and may
help to explain the phenomenon of self-relief after an
asthmatic attack.
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